🇺🇸 FDA
Pipeline program

ZYN002 Transdermal Gel Cannabidiol (CBD), ZYN002 Placebo Transdermal Gel

ZYN2-CL-033

Phase 3 small_molecule active

Quick answer

ZYN002 Transdermal Gel Cannabidiol (CBD), ZYN002 Placebo Transdermal Gel for Fragile X syndrome (FXS) is a Phase 3 program (small_molecule) at Harmony Biosciences Holdings with 1 ClinicalTrials.gov record(s).

Program details

Company
Harmony Biosciences Holdings
Indication
Fragile X syndrome (FXS)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials